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Bronchial asthma (BA) is a chronic inflammatory 
disease of the airways characterized by variable and 
recurring symptoms, reversible airflow obstruction 
and bronchospasm.  It has increasing incidence and 
prevalence worldwide.1  
Bronchial asthma is determined by many 
environmental and genetic factors, the clinical 
picture occurs as a result of complex interactions 
among genes, and the mutual influence of a 
genotype and environment upon each other.2,3 
Glucocorticoids (GCs) constitute the basic group 
of medication used to control inflammatory 
condition in patient with bronchial asthma; they 
regulate expression of specific genes within the cell 
nuclei via the Glucocorticoids \ Glucocorticoid 
receptor   complex (GC\GR).4 
It has been estimated that approximately 100 
genes are involved in the pathogenesis of asthma, 
NR3C1 gene (nuclear receptor subfamily 3, group 
C, member 1) is one of them, it encodes 
glucocorticoid receptor (GR) h-GR/NR3C1 which 
is localized on chromosome 5q31-q32 and consists 
of nine exons.5 The molecular mechanism of action 
of GCs involves binding of the specific 
ligand/glucocorticoid receptor to the sequences of 
regulator genes encoding the synthesis of anti-
inflammatory proteins determining the clinical 
effects of GCs.6 About 2571 polymorphisms of this 
gene are known, but the most common is the Bcl1 
gene polymorphism of GR.7 
 BclI (rs41423247) is formed as a result of 
changes in a single base. A C/G single nucleotide 
polymorphism (SNP) within the h-GR/NR3C1 gene 
promoter has been localized in the intron 647 bp 
away from the exon/intron binding site.8,9 BclI 
polymorphism (C/G) within h-GR/NR3C1 gene 
promoter demonstrates correlations with sensitivity 
to steroids, and may play an important role in the 
development of BA and resistance to GCs in severe 
bronchial asthma.10,11 
Original article 
Background: BclI is the promoter polymorphism observed within human 
glucocorticoid receptor gene (hGR/NR3C1) which plays an important role 
in the development of bronchial asthma (BA) and resistance to 
Glucocorticosteroids (GCs) in the severe BA. Objective: To assess the 
influence of BclI gene (rs41423247) polymorphisms on phenotypic 
expression of bronchial asthma in a group of Egyptian asthmatic children. 
Methods: This case control study included 135 asthmatic children with 
varying degrees of asthma severity. They were recruited from Allergy and 
Pulmonology Outpatient Clinic, Cairo University. Ninety healthy age and 
sex matched children served as the control group. Determination of BclI 
single nucleotide polymorphism (SNP) was done by polymerase chain 
reaction restriction fragment length polymorphism (PCR- RFLP). Results: 
Our results revealed that the variants of BclI polymorphism: CC/CG/GG 
was found with frequency 73.3%, 26.7%, 0% in control group. While in 
asthmatic children, their frequency was 42.2%, 51.1%, 6.7%, respectively. 
This revealed a significant difference in distribution between cases and 
control, similarly there was a significant difference in frequency of allele G 
between both groups (P-value <0.001). The frequency of allele G/C showed 
statistically significance association with increased severity of bronchial 
asthma (P-value<0.001), with uncontrolled asthma and hospitalization (P 
value <0.001). Conclusion: The Bcl I polymorphism of hGR/NR3C1 gene is 
significantly associated with bronchial asthma. The GG phenotype is 
significantly associated with increased susceptibility to the development of 
severe asthma and uncontrolled asthma symptoms, with increased risk of 
hospitalization. 
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Therefore, in the present study we aimed at 
assessing the influence of BclI gene polymorphisms 
on phenotypic expression of bronchial asthma in a 
group of Egyptian asthmatic children, using 
polymerase chain reaction restriction fragment 




This controlled cross-sectional study was carried 
out on 135 asthmatic children, all were recruited 
from the outpatient Allergy Clinic of the Allergy 
and Pulmonology Unit of the Specialized Children 
Hospital, Cairo University, along with 90 ages and 
sex matched healthy children as control with no 
history of atopic diseases, no chronic upper or 
lower airway diseases or history of 1st degree 
relative of BA.  
 
Ethical considerations 
The study objectives were explained to the patient's 
parents before data collection and informed consent 
was obtained. Study protocol was approved from 
the Ethical Committee at the Faculty of Medicine, 
Cairo University and is in accordance with the 
current version of the Helsinki Declaration.  
 
Methods 
Asthma diagnosis was established according to 
GINA, 2018 based on clinical asthma symptoms 
and lung function test. The degree of asthma 
severity, the level of control and the severity of 
asthma exacerbations was determined on the basis 
of GINA guidelines.1 The study included children 
above 6 years with varying degree of asthma 
severity; persistent (mild, moderate, severe), and 
were adherent to controller inhaled corticosteroids 
(ICS) (as verified by routine follow up in the 
outpatient Allergy clinic). Exclusion criteria were 
asthmatic children less than 6 years (since lung 
function measurements are considered to be 
unreliable in children < 6 years), patient using drugs 
which might induce resistance to glucocorticoids as 
rifampicin, ephedrine, phenobarbital and phenytoin 
or suffering from other chronic lung disease.  
 
Sample collection and processing 
For analyzing BclI promoter polymorphism using 
PCR-RFLP technique, two ml venous blood 
samples were collected from all study participants. 
DNA extracted using spin column (G-spin™ Total 




BclI polymorphism by PCR-RFLP 
Amplification of DNA segments for Bcl I SNP of 
h-GR/ NR3C1 was conducted by PCR using a 
forward primer 5`- GAG AAA TTC ACC CCT 
ACC AAC-3` and a reverse primer 5`- AGA GCC 
CTA TTC AAA CTG-3` .  
PCR reactions were carried out in a final volume 
of 25 ul using12.5 L MyTaq™ Red Mix (Bioline, 
London UK) and 1L Primers (20M each) and 
finally water is added . 
The PCR reaction tubes were placed in the 
thermal cycler (GeneAmp PCR system 9700, 
Germany). Primers Sequence and PCR cycling 
conditions are demonstrated in table in appendix. 
Amplification yielded a 418 bp amplicon which 
was further digested using 1ul of the restriction 
enzyme Fast Digest BclI (Thermo Scientific™ 
catalog number: ER0721) according to the 
manufacturing recommendations. Digested 
products were visualized using 2% agarose gel 
electrophoresis and allele assignments were 
homozygous G/G allele, for the undigested 418 bp 
DNA fragment as for the homozygous C/C allele it 
contains a recognition site for the BclI restriction 
enzyme, so the digestion yields two DNA 
fragments 263 and 151 bp while heterozygous C/G 
allele, yields three DNA fragments 418, 263 and 




Figure 1. Agarose gel electrophoresis of BclI 
digestion products of NR3C1 at position 646 
Lane 1: DNA marker (50 bp) 
Lane 2 and 4 represent heterozygous (CG) genotype, 3 
bands=418,263,155 bp 
Lane 3 shows homozygous (CC) genotype, 2 bands= 263, 155 
bp 
Lane 5 shows homozygous (GG) genotype, 1 band=418 bp 
 
Statistical Methods 
Data was coded and entered using the statistical 
package SPSS version 23. Data was summarized 
using mean and standard deviation for quantitative 
variables and frequencies (number of cases) and 
relative frequencies (percentages) for categorical 
variables. Comparisons between groups were done 
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using unpaired t test. For comparing categorical 
data, Chi square (2) test was performed. Exact test 
was used instead when the expected frequency is 
less than 5. Genotype and allele frequencies were 
compared between the disease and the control 
groups using logistic regression. Odds ratio (OR) 
with 95% confidence intervals was calculated. 
Univariate Logistic regressions was done to detect 
if BclI carrier act as independent predictor of 
asthma and asthma severity. P-values less than 0.05 
were considered as statistically significant. All 




Our study enrolled 135 asthmatic children along 
with 90 age and sex matched controls, with mean 
ages 9.3±3.6 years and 9.3±3.4 years, respectively. 
Seventy-eight (57.8%) of the cases were males and 
57 (42.2%) were females. Among controls, males 
were 52(57.8%) and females were 38(42.2%).  
According to asthma severity classification, 60 
(44.4%) asthmatic children had mild asthma, 45 
(33.3%) had moderate, and 30 (22.2%) had severe 
asthma. Included patients had different levels of 
asthma control. Basic demographic and clinical 
characteristics of the study population were shown 
in table 1.  
Frequency of BclI polymorphism of GR gene 
(CC, CG and GG) together with the distribution of 
its allele variants (C and G alleles) showed a 
significant difference between cases and control 
with P value <0.001. Carriers for G (GG, CG) allele 
were more susceptible to asthma than control, and 
homozygous for the G allele had a higher risk of the 
disease than the heterozygous, as were shown in 
table 2 and figure 2. 
On studying the correlation between asthma 
phenotype and BclI polymorphisms, the frequency 
of the allele G was significantly associated with 
increased severity of bronchial asthma in the 
investigated population; P value <0.001. Also, the 
frequencies of the GG genotype were associated 
with hospitalization with severe asthma 
exacerbation; P value <0.001. On analyzing the 
relation between BclI gene polymorphism and the 
associated allergic manifestations, there was a 
statistically significant difference between the 
frequency of allele G versus C regarding the 
presence of conjunctivitis and eczema; P value for 
each was <0.001, as were shown in table 3. 
These results were emphasized with post Hoc 
pairwise comparison test that showed a statistical 
significance on pairing BclI polymorphism (CC, 
GG) against asthma severity, hospitalization with 
severe asthma exacerbation and allergic 
conjunctivitis (p <0.001), furthermore pairing BclI 
polymorphism(CG, GG) showed statistical 
significance with both asthma severity and 
hospitalization with severe asthma with p <0.001 
and 0.003 respectively. Also pairing BclI 
polymorphism (CC, CG) showed statistical 
difference with asthma severity, allergic 
conjunctivitis and eczema with p= 0.006, <0.001, 
<0.001, respectively. 
Regarding the relation between BclI gene 
polymorphisms and level of asthma control among 
the studied group, there was increased incidence of 
uncontrolled asthma with the presence of the allele 
G, where in CC, CG, GG polymorphisms  
uncontrolled asthma was recorded in (0.0%, 64.3%, 
and 100%), respectively with  P value < 0.001, as 
shown in table 4. 
Post Hoc pairwise comparison test was done and 
showed statistically significant difference between 
well controlled and partially controlled and between 
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Table 1. Basic demographic and clinical data of the study population 
 





Age (years)  







Gender n (%) 
       Male 










Degree of Asthma severity n (%): 
       Mild persistent 
       Moderate persistent  
       Severe persistent 
Associated allergic manifestations n (%): 
       Allergic rhinitis 
       Conjunctivitis 
       Eczema 
       Food allergy  
Level of asthma control: 
        Well controlled  
        Partially controlled 
















SD: standard deviation, NA: not applicable, p<0.05 is statistically significant  
 
Table 2. Genotype and allele frequencies of the Bcl I polymorphisms in asthmatic 
children versus control group 
 









































OR: odds ratio, CI: Confidence interval , *P <0.05 is considered statistically significant,a:  Haldane-
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Table 3. Association between asthma phenotype and Bcl I polymorphisms 
 








Asthma severity  
     Mild persistent 
     Moderate persistent 

















 Hospitalization with severe asthma exacerbation 18 (31.6%) 33 (47.8%) 9 (100%) < 0.001 
Allergic rhinitis 36 (63.2%) 51(73.9%) 6(66.7%) 0.409 
Allergic conjunctivitis 15(26.3%) 57(82.6%) 9(100%) < 0.001 
Eczema  27(47.4%) 57(82.6%) 6(66.7%) < 0.001 
Food allergy 9(15.8%) 21(30.4%) 3(33.3%) 0.119 
*P < 0.05 is considered statistically significant.  
 
Table 4. Association between Bcl I polymorphisms and level of asthma control 
 
                 Group  
 
Bcl I polymorphisms 
Well controlled 
(n= 86) 






CC   53(61.6%) 4(11.4%) 0  
 
< 0.001 
CG 33(38.4%) 27(77.2%) 9(64.3%) 
GG  0(0%) 4(11.4%) 5(35.7%) 
*P < 0.05 is considered statistically significant. 
 
DISCUSSION 
We detected a statistically significant difference in 
genotype frequencies (GG, CG, and CC) of the 
BclI polymorphism of the human glucocorticoid 
receptor gene (hGR/NR3C1) in asthmatic patients 
compared with healthy controls. The present 
analysis of BclI polymorphism revealed a 
significant relationship between BclI gene 
polymorphisms and level of asthma control, where 
we observed an increased incidence of uncontrolled 
asthma in the presence of the allele G (CG, GG). 
Furthermore, this SNP is significantly associated 
with the severe asthma phenotype, what could be 
explained on the basis that, the observed 
polymorphic changes cause modifications of 
function or synthesis of glucocorticoid receptor 
which in turn affects the phenotypic characteristics 
of bronchial asthma.12 
Our findings are in line with a study conducted 
by Panek et al., 2012 which studied a group of 
Polish patients with severe asthma and observed a 
significant increase in the GG genotype among 
severe asthmatic patients compared with controls.12 
On the contrary, Panek et al. 2013 
demonstrated a lower frequency of the NR3C1 646 
C>G GG homozygote and a higher frequency of 
the CC homozygote among asthmatics (which 
included mild, moderate, and severe asthmatics) in 
comparison to the control group with no 
statistically significant differences in frequencies of 
NR3C1 646 C>G polymorphism when severe 
asthma was compared with the control group.13 
Similarly, Szczepankiewicz A. et al. study showed 
that polymorphisms of the GR gene are not 
associated with asthma susceptibility nor influence 
response to inhaled glucocorticoids in their 
sample.14 
Polymorphisms present within the h-
GR/NR3C1 gene may inhibit formation of GR/GCs 
complexes, reduce transcription and cause 
transrepression of the genes encoding proteins 
synthesized within the framework of cellular 
response to GCs and decreased expression of GR 
that leads to a reduced response to GCs and 
impairment of GCR.8,15 Accordingly, this study 
found that these genotypes (CG, GG) were 
associated with more loss of control of asthma 
symptoms causing hospitalization with severe 
exacerbations. 
 This study records for the first time that there is 
significant association between Bcl I 
polymorphism of h-GR/NR3C1 gene with the 
allergic conjunctivitis and eczema. But this was 
inconsistent with Mohamed et al. 2015 who 
reported that there is no relationship between atopy 
and this gene polymorphism, 16 but it is difficult to 
compare the results of our study with theirs due to 
their smaller sample size.  
In addition, the current study showed a 
significant difference in BclI genotypes and alleles 
frequencies between asthmatic children with 
different levels of asthma control, where, we 
demonstrated that well controlled asthmatic 
children had a greater frequency of the CC 
genotype distribution as well as C allele carriers 
than the partially controlled and uncontrolled 
asthmatics. This finding is supported with 
Osman et al. 
76 
Mohamed et al. 2015 who conducted a study on 
two groups of GCs sensitive and GCs resistant 
asthmatics adult Egyptian asthmatics and they 
detected a significant difference in genotype 
distribution between GCs sensitive and GCs 
resistant asthmatics, with a greater frequency of the 
CC genotype distribution as well as C allele 
carriers among GCs sensitive asthmatics than 
among GCs resistant asthmatics.16 Also, in 
agreement with our study, Khaled et al. 2020 noted 
among asthmatic children that the CC genotype 
was statistically associated with controlled asthma 
symptoms 3 months after treatment and the GG 
genotype was associated with poor asthma 
symptom control.17 
So, identification of genetic variation 
influencing treatment outcome in such 
heterogeneous disease (BA) with different 
endotypes and phenotypes might identify novel 
targets for biomarker-guided asthma treatment and 
preventative strategies.18,19 
In addition to this, the interaction with the 
environment that might play a major role in driving 
a predisposed genetic background toward severe 
and uncontrolled asthma phenotype, revealing the 
importance of the emerging Genome-wide 
interaction studies (GWIS) which assess the 
interaction between genome-wide genetic variance 
and environmental factors that might help in 
understanding this complex process.20 
 
CONCLUSION 
The Bcl I polymorphism of hGR/NR3C1 gene is 
significantly associated with bronchial asthma. The 
GG phenotype is significantly associated with 
increased susceptibility to the development of 
severe asthma and uncontrolled asthma symptoms, 
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